Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

enVVeno Medical Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- CASH AND INVESTMENTS ARE SUFFICIENT TO FUND CURRENT OPERATIONS THROUGH Q2 2027, NOT INCLUDING VENOVALVE COMMERCIALIZATION AND THE ENVVE IDE STUDY - CASH BURN OF $4.2 MILLION IN Q3 REMAINS IN LINE WITH PROJECTED QUARTERLY RANGE - ONGOING ENGAGEMENT WITH FDA FOR SUPERVISORY APPEAL OF THE VENOVALVE PMA DECISION WITH FEEDBACK EXPECTED BY THE END OF 2025 IRVINE, CA / ACCESS NEWSWIRE / OCTOBER 31, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER 2025. SUMMARY OF FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 THE COMPANY ENDED THE QUARTER WITH $31.0 MILLION IN CASH AND INVESTMENTS.

ENVVENO MEDICAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WATCH THE "WHAT THIS MEANS" VIDEO HERE IRVINE, CA / ACCESS NEWSWIRE / SEPTEMBER 26, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT ROBERT BERMAN, CHIEF EXECUTIVE OFFICER OF ENVVENO MEDICAL PARTICIPATED IN A VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT. AS PART OF THE SEGMENT, MR.

ENVVENO MEDICAL (NASDAQ:NVNO) PARTICIPATES IN VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT

IRVINE, CA / ACCESS NEWSWIRE / AUGUST 20, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT IT HAS RECEIVED A NOT-APPROVABLE LETTER FROM THE U.S. FOOD & DRUG ADMINISTRATION (FDA) IN RESPONSE TO ITS PREMARKET APPROVAL (PMA) APPLICATION FOR VENOVALVE, A SURGICAL REPLACEMENT VENOUS VALVE FOR TREATING SEVERE DEEP CHRONIC VENOUS INSUFFICIENCY (CVI). THE LETTER INDICATES THAT THE FDA COMPLETED ITS REVIEW OF THE VENOVALVE PMA APPLICATION AND DETERMINED THAT IT IS UNABLE TO APPROVE THE PMA FOR THE VENOVALVE IN ITS CURRENT FORM.

ENVVENO RECEIVES NOT-APPROVABLE LETTER FROM THE FDA FOR THE VENOVALVE(R)

- LIVE WEBCAST ON THURSDAY, AUGUST 21STAT 2:00 PM ET IRVINE, CA / ACCESS NEWSWIRE / AUGUST 15, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH BEING HELD VIRTUALLY AUGUST 19-21, 2025. DETAILS FOR THE PRESENTATION ARE AS FOLLOWS: DATE AND TIME: THURSDAY, AUGUST 21, 2025 AT 2:00 PM ET PRESENTER: ROBERT BERMAN, ENVVENO MEDICAL'S CHIEF EXECUTIVE OFFICER REGISTRATION LINK: HERE ABOUT WEBULL FINANCIAL WEBULL FINANCIAL IS A LEADING ONLINE BROKERAGE PLATFORM COMMITTED TO EMPOWERING SELF-DIRECTED INVESTORS WITH INNOVATIVE TOOLS AND CUTTING-EDGE TECHNOLOGY.

ENVVENO MEDICAL TO PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH

CLINICAL DATA AND COST-EFFECTIVENESS ANALYSIS DEMONSTRATES THE VENOVALVE WOULD PROVIDE BOTH BETTER HEALTH OUTCOMES AND LOWER COSTS COMPARED TO CURRENT STANDARD OF CARE TREATMENTS THE VENOVALVE COULD POTENTIALLY SAVE $5.9 BILLION ANNUALLY IN HEALTHCARE COSTS FOR THE APPROXIMATELY 2.5 MILLION U.S. PATIENTS WITH SEVERE CVI COMPANY TO HOST LIVE WEBCAST WITH LEAD AUTHOR OF THE COST-ANALYSIS MANUSCRIPT, TODAY, AUGUST 6TH, AT 12:00 PM ET; ACCESS THE WEBCAST HERE IRVINE, CA / ACCESS NEWSWIRE / AUGUST 6, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCEDPRELIMINARY FINDINGS FROM A VENOVALVE HEALTH ECONOMIC STUDY, WHICH INDICATE THAT THE VENOVALVE WOULD BE A COST-EFFECTIVE TREATMENT OPTION FOR PATIENTS WITH SEVERE CHRONIC VENOUS INSUFFICIENCY (CVI) CAUSED BY DEEP VALVULAR INCOMPETENCY. THE COMPANY ANNOUNCED IT WILL HOST A LIVE WEBCAST TO DISCUSS THE COST-EFFECTIVENESS ANALYSIS RESULTS TODAY, WEDNESDAY, AUGUST 6TH AT 12:00 PM ET (DETAILS BELOW).

HEALTH ECONOMIC STUDY SHOWS THAT ENVVENO MEDICAL'S VENOVALVE(R) WOULD BE A COST-EFFECTIVE TREATMENT OPTION FOR PATIENTS WITH SEVERE CHRONIC VENOUS INSUFFICIENCY

- ENVVENO IS DEVELOPING THE VENOVALVE AS A POTENTIAL TREATMENT OPTION FOR THE APPROXIMATELY 2.5 MILLION PATIENTS IN THE U.S. SUFFERING FROM SEVERE DEEP CHRONIC VENOUS INSUFFICIENCY - FDA DECISION EXPECTED IN 2H'2025 - ACCESS THE "WHAT THIS MEANS" SEGMENT HERE IRVINE, CA / ACCESS NEWSWIRE / AUGUST 4, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT IT PARTICIPATED IN A VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT ENTITLED, "ENVVENO MEDICAL - MAKING VEINS WORK AGAIN - HOW PRESIDENT TRUMP'S CVI DIAGNOSIS IS RAISING AWARENESS." ROB BERMAN, CEO AND DR. MARC GLICKMAN, CMO OF ENVVENO MEDICAL DISCUSSED THE PROGRESSIVE NATURE OF CHRONIC VEINOUS INSUFFICIENCY AND WHETHER PRESIDENT TRUMP MAY ONE DAY BE A CANDIDATE FOR THE VENOVALVE FOLLOWING U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL.

ENVVENO MEDICAL PARTICIPATES IN A NEW VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT TO DISCUSS HOW PRESIDENT TRUMP'S RECENT CVI DIAGNOSIS MAY IMPACT THE COMPANY

- CASH BURN OF $3.8 MILLION IN Q2 REMAINS IN LINE WITH PROJECTED QUARTERLY RANGE - CASH AND INVESTMENTS ARE SUFFICIENT TO FUND OPERATIONS THROUGH Q3'2026 AT CURRENT CASH BURN RATE - COMMERCIAL READINESS ACTIVITIES UNDERWAY FOR A PHASED LAUNCH OF VENOVALVE SUBJECT TO FDA DECISION EXPECTED IN 2H'2025 - IDE SUBMISSION FOR ENVVE ON TRACK FOR 2H'2025 IRVINE, CA / ACCESS NEWSWIRE / AUGUST 1, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO MEDICAL" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER 2025. "AS THE RECENT HEADLINES AROUND CVI CONFIRMED, CVI IS A PERVASIVE AND A PROGRESSIVE DISEASE THAT IS ESPECIALLY DEBILITATING ONCE IT BECOMES SEVERE.

ENVVENO MEDICAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- VIDEO WEBCAST NOW AVAILABLE ON-DEMAND IRVINE, CA / ACCESS NEWSWIRE / JULY 22, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT ROB BERMAN, CEO OF ENVVENO, PARTICIPATED IN THE VIRTUAL INVESTOR "WHAT'S YOUR STORY" SUMMER SPOTLIGHT ON-DEMAND CONFERENCE. AS PART OF THE SEGMENT, MR.

ENVVENO MEDICAL PARTICIPATES IN THE VIRTUAL INVESTOR "WHAT'S YOUR STORY" SUMMER SPOTLIGHT ON-DEMAND CONFERENCE

INTERIM TWO-YEAR FOLLOW-UP DATA FROM 42 SUBJECTS IN THE VENOVALVE PIVOTAL TRIAL SHOW SUSTAINED CLINICAL IMPROVEMENT AND CONTINUED PATIENT BENEFIT AT 24 MONTHS COMPARED TO BASELINE 83% OF SUBJECTS MAINTAINED A CLINICALLY MEANINGFUL BENEFIT WITH A 3 OR MORE POINT IMPROVEMENT IN REVISED VENOUS CLINICAL SEVERITY SCORE (RVCSS) 9.1 POINT AVERAGE RVCSS IMPROVEMENT AMONG THE CLINICALLY MEANINGFUL BENEFIT COHORT SUBJECTS EXPERIENCED A MEDIAN 74% IMPROVEMENT IN LEG PAIN INTERIM FOLLOW-UP DATA INDICATE SUSTAINED IMPROVEMENTS ACROSS ALL VENOUS-SPECIFIC QUALITY-OF-LIFE (QOL) INDICATORS A DECISION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON THE VENOVALVE IS ANTICIPATED IN THE SECOND HALF OF 2025 COMPANY TO HOST LIVE WEBCAST WITH PRESENTING PRINCIPAL INVESTIGATOR, TODAY, JUNE 6TH AT 11:20 AM ET / 10:20 AM CT - ACCESS THE WEBCAST HERE IRVINE, CA / ACCESS NEWSWIRE / JUNE 6, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, TODAY ANNOUNCED THAT INTERIM TWO-YEAR FOLLOW-UP DATA ON 42 SUBJECTS FROM THE 75 PERSON VENOVALVE U.S. PIVOTAL TRIAL WILL BE PRESENTED TODAY BY LEAD ENROLLER DR. CASSIUS IYAD OCHOA CHAAR, AT THE SOCIETY FOR VASCULAR SURGERY (SVS) 2025 VASCULAR ANNUAL MEETING (VAM25) BEING HELD JUNE 4-7, 2025 IN NEW ORLEANS, LA. ADDITIONALLY, THE COMPANY ANNOUNCED IT WILL HOST A LIVE WEBCAST TO DISCUSS THESE INTERIM RESULTS TODAY, FRIDAY, JUNE 6TH AT 11:20 AM ET / 10:20 AM CT (DETAILS BELOW).

POSITIVE INTERIM 2-YEAR DATA FROM ENVVENO MEDICAL'S VENOVALVE PIVOTAL STUDY TO BE PRESENTED TODAY AT THE SOCIETY FOR VASCULAR SURGERY (SVS) 2025 VASCULAR ANNUAL MEETING

IRVINE, CA / ACCESS NEWSWIRE / MAY 19, 2025 / ENVVENO MEDICAL CORPORATION (NASDAQ:NVNO) ("ENVVENO" OR THE "COMPANY"), A COMPANY SETTING NEW STANDARDS OF CARE FOR THE TREATMENT OF DEEP VENOUS DISEASE, ANNOUNCED THE APPOINTMENT OF JENNIFER BRIGHT AS CHIEF FINANCIAL OFFICER, EFFECTIVE TODAY, MAY 19, 2025. MS. BRIGHT BRINGS MORE THAN 25 YEARS OF FINANCIAL AND STRATEGIC LEADERSHIP EXPERIENCE BUILT ACROSS SEVERAL COMMERCIAL-STAGE MEDICAL DEVICE AND PHARMACEUTICAL COMPANIES INCLUDING BIOLASE, SPECTRUM PHARMACEUTICALS, APRIA HEALTHCARE, SMILE BRANDS, AND TELEFLEX MEDICAL, AS WELL AS TECHNICAL ACCOUNTING AND AUDITING EXPERIENCE AT PRICEWATERHOUSECOOPERS LLP.

enVVeno Medical Corporation

NVNO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

enVVeno Medical Corporation

NVNO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVNO